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Paranoia, phobias, and other disorders involving abnormal fear, share a 
common dysregulation of intrusive thought. These disruptive thoughts elicit 
defensive behavioural responses in the absence of a genuine threat. To 
understand the neural basis of fear responding the present study employed 
an animal paradigm of abnormal fear involving the chronic administration of d-
amphetamine. D-amphetamine (2.5 μg / 0.5 μl side) was infused into the 
ventral tegmental area (VTA) – a region whose dopaminergic projections are 
critical to fear neurocircuitry – prior to each of three extinction sessions. As d–
amphetamine is especially effective in potentiating the release of mid–brain 
dopamine, and the hyperactivity of dopaminergic transmission has been 
repeatedly implicated in the genesis of abnormal fear, it was predicted that an 
infusion of the drug prior to extinction would result in an extinction deficit. The 
chronic administration of amphetamine to the VTA prior to extinction sessions 
was found to interfere with the subject’s ability to extinguish a previously 
conditioned fear, as tested on a subsequent fear-potentiated startle test. This 
result was not due to chronic amphetamine administration enhancing the 
baseline levels of conditioned fear. Administration of amphetamine (2.5 μg / 
0.5 μl side) to a terminal region of the VTA dopaminergic projections, the  
basolateral amygdala, did not produce the extinction deficits yielded from the 
VTA. This regional specificity raises interesting questions about the role of 
somatodendritic dopamine release in the maintenance of abnormal fear.  
 
 XI
As an adjunct to the primary aim of this study, the effects of behavioural 
sensitisation to psycho-stimulants were also assessed. This helped to 
establish that the infusions were reaching the correct target area and 
additionally, the behaviourally sensitised state of the subjects further helped to 
align the findings of this study with the literature surrounding psycho-stimulant 




I N T R O D U C T I O N  
 
Fear, the evolutionary survival tool, functions as an emotional motivator and a 
behavioural precipitator. For the last century, the neural underpinnings of this 
emotional state have been sought. Gradually, as the neurocircuitry involved 
becomes more apparent, so too do the number of questions that remain 
unanswered by these neurobiological studies. One of the most conspicuously 
unsolved areas is the neurocircuitry involved in abnormal fear. Adaptively 
disadvantageous, abnormal fear may quite simply be a malfunction of the 
neurocircuitry underlying normal fear. However, the possibility remains that 
rather than a simple malfunction of the known neurocircuitry, abnormal fear has 
distinct neural underpinnings. In a field of research still in its’ infancy the quest 
continues to establish the neural basis of abnormal fear.  
 
 
1 Emotionality and the mesolimbic system 
 
1. 1. Fear  
Fear is the emotional state which arises as part of a biological response to a 
threatening stimulus. Each species has an inherent repertoire of defensive 
behaviours that the emotion of fear will elicit. These defensive behaviours, 
educed by fear, serve as potent tools in the survival of a species. In mammals, 
behaviours that are usually associated with fear responding are, freezing, 
increased startle amplitude,, autonomic changes, and hypoalgesia (Rosen & 
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Schulkin, 1998). The quintessential characteristic of fear is that it is an 
adaptively advantageous emotion. 
 
As normal fear can be characterised by its’ adaptive benefits, abnormal fear can 
be defined in terms of its’ maladaptive nature. Abnormal fear is the physiological 
manifestation of fear in the absence of a real or immediate threat. The arousal 
of the autonomic nervous system occurs without conscious control, and it 
remains a contentious issue whether the centralised emotional state of fear 
occurs prior to, concurrently with, or as a result of, this physiological arousal. 
1. 2. Measurement of Fear and Fear – Potentiated Startle 
To experimentally produce the centralised emotional state of fear animal 
models commonly employ Pavlovian conditioning. Pavlovian fear conditioning 
involves the prolonged pairing of a non-aversive stimulus, known as the 
conditioned stimulus (CS), with a naturally aversive stimulus, known as the 
unconditioned stimulus (UCS). Through this process the unconditioned stimulus 
indirectly acquires aversive properties. The subject will then display fearful 
behaviour when presented with the unconditioned stimulus, due to its prior 
associations. The conditioned fear may then be extinguished by the continuous 
presentation of the unconditioned stimulus without the aversive consequence. If 
the conditioned fear is unable to be extinguished, it is considered that the 
subject has acquired a maladaptive or abnormal fear of the stimulus.  
One paradigm commonly used in animal studies to measure fear is known as 
fear-potentiated startle. Startle is a naturally occurring reflex to a fear-evoking 
stimulus. 
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If fear is viewed as a motivational state, it should augment behavioural 
responses that occur simultaneously with it. This hypothesis led to the 
investigation of the effect of a fearful state on the acoustic startle reflex (Brown, 
Kalish, & Farber, 1951). Acoustic startle amplitudes were found to increase 
relative to baseline in the presence of a fear-evoking stimulus.(Brown et al., 
1951). It is the augmentation of the startle response rather than startle response 
itself that is the measure of fear. By measuring the augmentation of a subject’s 
startle response, one can infer from its’ potency, the level of fear the subject 
experiences when presented with that particular fear - evoking stimulus. The 
startle paradigm has considerable face validity as a behavioural manifestation 
of fear in animals primarily due to its’ ability to be reliably produced across 
species . Acoustic startle has been widely used as a reliable nonverbal index of 
fear and anxiety in both human (Baas, Nugent, Lissek, Pine, & Grillon, 2004; 
Greenwald, Bradley, Cuthbert, & Lang, 1998; Lang, 1995) and animal (Falls & 
Davis, 1995; Hitchcock & Davis, 1991; Kim & Davis, 1993) subjects, after the 
presentation of aversive stimuli. One desirable advantage of the acoustic startle 
paradigm as an experimental tool, is that the primary measure, the acoustic 
startle response, is a reflexive action rather than an operant response. The 
benefits of measuring a reflex rather than an operant response are two-fold, 
firstly because startle response will have a pre-existing baseline greater than 
zero, it can be either enhanced or diminished under experimental conditions, 
whereas any learned behaviour will have an initial baseline of approximately 
zero (Koch, 1999). Secondly,  the acoustic startle response employs relatively 
straightforward and established circuitry in the lower brainstem, compared to 
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the more complicated cognitive processing required for operant responding 
(Koch, 1999).  
Fear potentiated startle, as a phenomenon can be viewed as an anticipatory 
defensive behaviour (Davis, Falls, Campeau, & Kim, 1993; Misslin, 2003) . In 
the fear - potentiated startle paradigm, the conditioned stimulus produces a 
defensive behaviour in response to a potential threat. The antithesis of this 
behaviour would be defensive behaviour that is elicited by an actual and 
immediate threat. Fear - potentiated startle amplitudes peak, at a time 
consistent with the inter-stimulus-interval of the prior CS-UCS pairing  (Davis et 
al., 1993). Thus illustrating the anticipatory nature of fear potentiated startle. 
1. 3. Extinction of Fear 
The continued presentation of a CS without the UCS will result in a gradual 
weakening of association culminating in the complete inability of the CS to 
produce the conditioned response in the subject (Pavlov, 1924). Prima facie, 
extinction of pavlovian conditioned fear is a form of suppression or internal 
inhibition (Pavlov, 1924) of a previously learned association between the CS 
and the UCS. Interestingly, it appears that the inhibition of the conditioned 
association is not permanent and the association may spontaneously recur 
(Pavlov, 1924).  The proposition that extinction is merely the temporary 
inhibition of an excitatory conditioned response is given credence by the 
phenomenon of spontaneous recovery. Implicit in the concept of spontaneous 
recovery is the assumption that conditioned inhibition is stable over time and 
resistant to external disruptors. Rescorla (1969) however argues that the 
assumption that conditioned inhibition is more robust than conditioned 
excitation, is not supported by empirical evidence.  
 5
 
Conversely, it has been postulated that rather than the mere suppression of a 
conditioned association, extinction is actually another learned association, this 
time between the CS and the absence of the UCS. Konorski (1948) proposed 
that the excitatory neural connection governing the conditioned reflex gradually 
diminishes over time as the neural connection governing the inhibitory 
connection strengthens. In this context the conditioned association (CS→ UCS) 
is retrieved with each presentation of the CS in the original training context. 
Extinction learning is simply the pairing of the CS with the Non-UCS, in the 
original training context (Bouton, 1993). As extinction training unfolds the 
number of exposures to the CS→ Non-UCS pairing increases and the retrieval 
of that association begins to interfere with the retrieval of the initial CS→ UCS 
association. Subsequent phenomena, such as spontaneous recovery and 
renewal, can be interpreted as a failure to retrieve the extinction association 
(Bouton, 1993).   
1. 4. Neural Circuitry of Fear 
Pavlovian conditioning develops a cue-specific fear in the subject, as opposed 
to a non-specific or generalised fear state (Rosen & Schulkin, 1998). This 
suggests amygdala involvement in the neural basis of pavlovian conditioned 
fear, as amygdala lesions have been found to block the acquisition of cue-
specific fear potentiated startle (Hitchcock & Davis, 1991). The amygdala is the 
brain structure responsible for receiving the sensory inputs that arise from a 
fear-evoking stimulus and for producing the requisite behavioural response 
(Rosen & Schulkin, 1998). In a pavlovian conditioned paradigm such as fear-
potentiated startle, stated in a rudimentary fashion, the external input from the 
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CS is filtered by the amygdala and the appropriate conditioned response is 
activated (LeDoux, 1998). Specifically, with the acoustic startle response, the 
auditory input is transmitted via the cochlear nuclei complex to the caudal 
pontine reticular nucleus (PnC) and subsequently to the motor neurons which 
initiate the startle response (as summarised in (Koch, 1999)). Synaptic 
transmission between the PnC and the amygdala appears to be the point at 
which conditioned fear enhances the motoric startle response (Davis et al., 
1993). The basolateral nucleus of the amygdala receives sensory input from all 
sources; in turn the basolateral nucleus projects this information to the central 
nucleus of the amygdala. The central amygdaloid nucleus projects to the PnC of 
the acoustic startle circuit. Learned fear associations about the CS, are 
triggered by sensory input and this is subsequently relayed through the nuclei of 
the amygdala to the PnC of the startle circuit (Davis et al., 1993). In this way 
conditioned fear produces the enhancement of the acoustic startle response 
characteristic of fear potentiated startle.  
 
The importance of the amygdala in fear neural circuitry extends far beyond its’ 
seemingly simple relay-role in fear-potentiated startle. As previously alluded to, 
the amygdala is necessary in the acquisition of cue specific fear- potentiated 
startle and  is also necessary for expression of the response (Hitchcock & 
Davis, 1991). Just as the amygdala appears important in both the acquisition 
and expression of fear potentiated startle, so too does dopamine within the 
amygdala. Kokkinidis and Waddington-Lamont (1998) found that the infusion of 
the dopamine D1 receptor antagonist SCH23390 into the amygdala complex 
resulted in decreased expression of fear-potentiated startle. Similarly, Guracci 
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and colleagues (1999) found that infusions of SCH23390 into the amygdaloid 
complex decreased acquisition and expression of freezing, whereas SKF82958 
(a D1 receptor agonist) increased acquisition and expression of freezing. 
Furthermore, amphetamine, a dopamine agonist, has been reported to 
potentiate the response of the amygdala during the perceptual processing of 
fearful faces, in human subjects (Hariri et al., 2002).The amygdala receives the 
majority of its’ dopaminergic projections from a region known as the ventral 
tegmental area (VTA), located on the floor of the mesencephalon. 6–OHDA 
lesions of the VTA were found to reduce dopamine levels in the amygdala by 
around 90% (Oades & Halliday, 1987). As dopamine appears to play an 
important role in the functioning of the amygdala in conditioned fear, logic would 
suggest that the major contributor of amygdaloid dopamine, namely the VTA, 
should be investigated in relation to conditioned fear.     
 1. 5. Ventral Tegmental Area 
The amygdala although important in conditioned fear, is however, just one 
component of an interconnected network involved in the acquisition, expression 
and extinction of conditioned fear. The ventral tegmental area (VTA) is another 
such constituent of the neurocircuitry involved in conditioned fear. Connectively, 
the amygdala and the VTA interact via the mesolimbic pathway. The VTA 
projects dopamine fibres directly to the amygdala and indirectly receives 
dopamine projections from the amygdala via the pre-frontal cortex (Oades & 
Halliday, 1987).  
 
The ventral tegmental area, is a mid - brain region that is known to play a 
crucial role in the impetus behind behaviour.  Located on the floor of the 
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mesencephalon the ventral tegmental area is medial to the substantia nigra and 
ventral to the red nucleus (Swanson, 1982). The estimated 14,000 cells of the 
VTA mainly consist of small to medium sized neurons. Approximately two-thirds 
of these cells are dopaminergic, making the VTA one of the most dopamine rich 
regions of the midbrain. The efferent projections of the VTA can be divided into 
three major components. The first of these pathways projects through the 
medial forebrain bundle to a variety of forebrain regions including, among 
others, the nucleus accumbens and the amygdala. The second major projection 
is to the thalamus while, the third projection descends to the periaqueductal 
grey area, the locus coeruleus and the median raphe nucleus (Swanson, 1982).  
 
The VTA with its’ abundant source of mid-brain dopaminergic neurons, has 
been implicated in behavioural sensitisation, drug dependence and self 
stimulation studies (for a review see (Bonci, Bernardi, Grillner, & Mercuri, 
2003)). A massive 70 % of all VTA projections are dopaminergic (Swanson, 
1982) highlighting the importance of the VTA in the distribution of dopamine.  
1. 6. Dopamine, Fear-Potentiated Startle & the Mesolimbic System 
The mesolimbic pathway is a dopaminergic projection originating in the VTA 
and projecting to the nucleus accumbens and the amygdala (Swanson, 1982, 
Oades & Halliday, 1987). The VTA is necessary for the expression of fear-
potentiated startle (Borowski & Kokkinidis, 1996). NMDA-induced lesions of the 
VTA resulted in the inability of subjects to express an augmentation of fear in 
the presence of a previously conditioned stimulus (Borowski & Kokkinidis, 
1996).  In particular the dopaminergic projections of the VTA are crucial to the 
expression of conditioned fear as infusions of the dopamine D2/3 receptor 
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agonist, quinpirole, into the VTA suppressed fear-potentiated startle (Borowski 
& Kokkinidis, 1996).  
 
Connectively, the dopaminergic projections of VTA and their terminal regions 
are also heavily involved in the acquisition and expression of fear- potentiated 
startle. Quinpirole, a dopamine autoreceptor agonist which reduces the 
rewarding efficacy of VTA stimulation (Ranaldi & Beninger, 1994), has been 
found to block fear-potentiated-startle, when administered to the VTA (Borowski 
& Kokkinidis, 1996; Gifkins, Greba, & Kokkinidis, 2002).  Hitchcock and Davis 
(1991) found that lesions in numerous places along the pathway from the 
central nucleus of the amygdala to the brainstem startle circuit blocked fear-
potentiated startle. The mesoamygdaloid dopaminergic pathway is also critical 
for the retrieval of fearful associations created during fear conditioning (Nader & 
LeDoux, 1999). Inhibition of dopaminergic activity on this mesolimbic pathway 
interferes with the retrieval of the previously learnt CS → UCS association. The 
pharmacological inhibition of dopamine activity in the VTA or the basolateral 
amygdala (BLA) with either quinpirole or SCH23390 results in this retrieval 
impairment (Nader & LeDoux, 1999). Therefore, irrespective of the terminal or 
somatic nature of the dopamine neurons of the mesolimbic pathway, their 
inhibition results in the same impairment.    
 
Electrical stimulation at a variety of levels in the VTA produced significant 
increases in acoustic startle amplitudes (Borowski & Kokkinidis, 1996). 
Stimulation of the VTA appears to produce the same hyperdopaminergic state 
in the rat brain that chronic administration of psychomotor stimulants does 
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(Watanabe, Morimoto, Nakamura& Suwaki, 1998). Dopamine receptor 
antagonists have been found to successfully moderate the behavioural effects 
of VTA stimulation (Watanabe, et al, 1998). Interestingly, the chronic systemic 
administration of dopamine agonist, methamphetamine, reduced the threshold 
of electrical stimulation required in the VTA to achieve pre-determined abnormal 
behaviours (Watanabe, et al, 1998).These findings emphasise the importance 
of hyperdopaminergic activity in the mesolimbic system and in particular in the 
VTA during the abnormal behaviour seen in both idiopathic and drug induced 
psychosis. 
 
2 Psychomotor Stimulants, Fear & the Mesolimbic System 
 
2. 1. Psychomotor Stimulants and Fear 
Psychomotor stimulants juxtapose reward and aversion. Commonly abused for 
their euphoric properties, psychomotor stimulants such as cocaine and 
amphetamine are capable of inducing both joy and fear. These disparate effects 
are anatomically distinct yet causally similar. Intracranial microinjections of 
amphetamine into a variety of brain regions, showed an anatomical dissociation 
of the rewarding and aversive effects of the drug. The nucleus accumbens 
proved to be vital for the rewarding effects, while the area postrema 
demonstrated its’ importance in the aversive effects of amphetamine (Carr & 
White, 1986). 
 
The capacity of psychomotor stimulants to pharmacologically induce negative 
emotional states has proven to be a valuable research tool. Discovered 
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clinically  (Young & Scoville, 1938), the prolonged administration of 
amphetamine results in the subject developing a state similar to the paranoid 
psychosis observed in those with schizophrenia (Angrist, Sathananthan, Wilk, & 
Gershon, 1974; Griffith, Cavanaugh, Held, & Oates, 1970). Characteristic of this 
type of psychosis are paranoid ideations, themselves indicative of exaggerated 
and abnormal fear in the individual. Thus chronic amphetamine exposure has 
been utilised in animal research as a paradigm of abnormal fear. Additionally, 
the psychosis induced by prolonged amphetamine abuse can be reinstated 
spontaneously, by re-exposure to amphetamine or by exposure to psycho-
social stressors  (Griffith et al., 1970; Sato, Numachi, & Hamamura, 1992; Yui, 
Goto, Ikemoto, & Ishiguro, 2000).The latent continuity of amphetamine 
psychosis is perhaps indicative of an underlying and permanent inability within 
the individual to extinguish inappropriate associations.  
2. 2. Systemic Studies 
Systemic administration of psychomotor stimulants appears to globally enhance 
fear. Prolonged administration of cocaine increased the expression of 
conditioned fear in subjects evaluated with a FPS paradigm (Willick & 
Kokkinidis, 1995). Acute administrations of cocaine, d-amphetamine and 
SKF38393 ( a D1 receptor agonist) prior to extinction training retarded the 
subjects’ ability to cease fearing the CS  (Borowski & Kokkinidis, 1998). The 
curbing of extinction learning by psychomotor stimulants suggests the drugs 
possess fear - enhancing properties. Chronic administration of cocaine prior to 
extinction training was also found to produce deficits in extinction learning 
(Willick & Kokkinidis, 1995). Furthermore, the re-administration of a single dose 
of either cocaine or SKF38393 is sufficient to reinstate previously extinguished 
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conditioned fear  (Borowski & Kokkinidis, 1998).  Pre- exposure to cocaine 
produces long-lasting changes to fear potentiated startle (Gordon & Rosen, 
1999). During the withdrawal period, following chronic administration of cocaine, 
subjects showed an increase in startle responses both to a noise burst and to a 
conditioned stimulus. The increase in startle is indicative of heightened anxiety 
during the withdrawal period. It also suggests that the stimulant is in some way 
facilitating the fear association, to an explicit cue, over a prolonged period of 
time.    
 
2. 3.  Pharmacological Actions of Amphetamine 
The primary action of amphetamine in the central nervous system is to 
potentiate the release of dopamine. The acute effects of amphetamine on 
dopaminergic neuronal function are dual in nature. Pre-synaptically, the 
stimulant causes an increase in the release of dopamine from the neuron, while 
concurrently  decreasing dopamine reuptake by the pre-synaptic neuron 
(Lieberman, Kinon & Loebel, 1990). Consequently, the acute actions of 
amphetamine are an increase of dopamine levels in the synaptic cleft.  The 
psychomotor stimulant has been found to affect the dopaminergic neurons of 
the CNS in both an excitatory and inhibitory manner (Shi, Pun, Zhang, Jones & 
Bunney, 2000). This inhibition and excitation is mediated by the dopamine D2  
receptor. The excitatory effect of amphetamine on the dopamine cell is evident 
when the D2 receptor is blocked and the inhibitory effect is seen when it 
modulates dopamine cell firing (Shi et al., 2000). This finding suggests that 
amphetamine has a dual effect on dopamine cells, namely DA mediated 




3 Psychomotor Sensitisation 
  
3.1.  Sensitisation 
Sensitisation occurs when chronic exposure to a stimulus, produces long-lasting 
enhancement of its normal physiological effects. The phenomenon of 
pharmacological sensitisation can be elicited following repeated administration 
of a particular drug by a single challenge presentation of that substance (for a 
review see Vanderschuren & Kalivas, 2000). Pre-exposure to that particular 
drug, will ensure that the individual is sensitised to its’ effects and consequently 
the challenge-exposure will result in heightened effectiveness of the substance. 
The sensitisation process implies that the threshold for activation has become 
lower over time (Rosen & Schulkin, 1998). The phenomenon of sensitisation is 
indicative of hyperexcitability of the neurocircuitry involved.  
 
Sensitisation is a long – lived phenomenon. The enduring nature of 
neurochemical sensitisation is supported by evidence that individuals, who have 
previously attained a state of methamphetamine induced psychosis, will relapse 
given a single dose of methamphetamine following a period of abstinence 
(Sato, Chen, Akiyama & Otsuki, 1983). The acute dose of methamphetamine 
given may be markedly smaller than doses taken during the period of abuse, 
none of which were sufficient to induce psychosis. The relapse into the 
psychotic state is indicative of  long-lasting sensitisation to the effects of the 
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stimulant. Interestingly, the concurrent administration of the neuroleptic 
haloperidol, a potent dopamine receptor blocker, prevented relapse when the 
subject was given a challenge-dose of methamphetamine following a period of 
abstinence (Sato, et al., 1983). Following the discontinuation of haloperidol, a 
single dose of methamphetamine was sufficient to re-induce psychotic 
symptoms. The longevity of behavioural sensitisation is such that even several 
years later, a single presentation of the abused drug can induce psychosis 
(Sato, et al., 1983). The long-lived nature of sensitisation indicates that 
psychomotor stimulants modify brain functioning for a prolonged period of time 
following their administration.  
 
The dormant nature of behavioural sensitisation bears strong similarity to the 
unseen development of schizophrenia and like many psychotic episodes can be 
triggered either by an external stressor or pharmacologically. Re-exposure to a 
chronically administered drug is not the only catalyst of behavioural 
sensitisation. Other factors such as stress may trigger behavioural sensitisation 
(Sato, Chen, Akiyama & Otsuki, 1983, Yui, Goto, Ikemoto & Ishiguru, 2000). 
Interestingly, stress may exacerbate sensitisation to psychomotor stimulants. 
Castner and Goldman-Rakic (1996) reported that the more baseline “stress” an 
animal exhibited, the more pronounced the effect of amphetamine on the 
abolition of stereotypic behaviours during sensitisation. In addition to this, they 
also reported an exacerbation of stressful responses by the subjects during 
amphetamine sensitisation. These stressful responses included behaviours 
such as self - biting and saluting.  
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3. 2. Neuroanatomical Substrates of Sensitisation 
The VTA has proven to be necessary for both the development and inhibition of 
sensitisation to psychomotor stimulants (Jones, Kornblum & Kauer, 2000). 
Acute infusions of amphetamine into the VTA produce no discernable increase 
in locomotor activity (Kalivas & Weber, 1988) in contrast to the effects of 
peripheral administration, where an increase in locomotor activity is legend. 
Interestingly, a single infusion of amphetamine to the nucleus accumbens 
produces a significant and dose-dependent increase in locomotor activity (Carr 
& White, 1986, Cador, Bjijou & Stinus, 1995).  The total dissociation of these 
two regions and their role in behavioural sensitisation is further exemplified by 
the chronic administration of psychomotor stimulants. Repeated intra-cranial 
amphetamine infusions in the ventral tegmental region will result in long-lasting 
changes to the sensitivity of that region. A challenge presentation of 
amphetamine, either peripherally or intra – cranially, following chronic 
administration results in heightened behavioural activity (Kalivas & Weber, 
1988, Hooks & Jones, 1992, Cador & Bjijou, 1995). Both cocaine and 
amphetamine chronically administered intra-cranially to either the A9 
(substantia nigra) region, or the A10 (ventral tegmental area) resulted in a 
potentiation of the psychomotor stimulant effects when administered 
peripherally. However, intra - cranial administration of the stimulants to the 
terminal regions of the dopamine cells of the A9 and A10 regions, namely the 
nucleus accumbens, the striatum and the lateral ventricle, did not result in any 






4 Rationale and Hypothesis 
 
A dual theme gains clarity from within the literature surrounding the neural basis 
of abnormal fear. The potentiation of dopamine, whether organically or 
synthetically, and activity of the mesolimbic system both seem to play a crucial 
role in abnormal fear. More specifically, two areas within the mesolimbic 
system, namely the ventral tegmental area (VTA) and the basolateral amygdala 
(BLA), emerge as a key regions  underlying the behavioural manifestations of 
abnormal fear. An increasing amount of evidence begins to converge on the 
hypothesis that the VTA and its dopaminergic neurons are critical to the 
acquisition of conditioned fear, whilst the BLA is important in the processing, 
responding and extinction of fearful stimuli. However, very little is known about 
how the dopaminergic neurons of the mesolimbic system are influencing the 
extinction of fearful associations . Therefore, by using a dopamine agonist 
whose pharmacological actions are known, namely amphetamine, we can hope 
to uncover more about the actions of dopamine in the VTA and the BLA and 
their ramifications on the extinction of conditioned fear. Amphetamine has 
previously been found in systemic studies to (Kumar, 1971) retard fear 
extinction.  In particular the aim of this study is to investigate the effects of 
amphetamine, infused into the VTA and the BLA , on the extinction of pavlovian 
conditioned fear responses. It is hypothesised that amphetamine administered 
to the VTA, the base of the mesolimbic system,  immediately prior to extinction 
will significantly impair the extinction of a previously conditioned fear 
association. Whereas the effects of a central infusion of amphetamine to the 
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BLA are likely to differ from those of the VTA due to the contrasting terminal 
nature of the dopamine neurons in this region.  In addition, the study will also 
seek to investigate a possible link between the  behaviourally sensitising effects 






 5        M E T H O D 
 
5. 1. Subjects 
Male Wistar rats (University of Canterbury) weighing between 300 - 400g at the 
time of surgery, served as subjects in this study. The animals were group -
housed throughout the study on a 12 hour light/dark cycle, with the light cycle 
beginning at 0800 and the dark cycle beginning at 2000. Both the light and dark 
cycles took place within a constant climatically controlled (21°C) colony 
environment. Behavioural testing occurred during the light portion of the cycle. 
Throughout the study subjects had free access to food and water. 
 
5. 2. Apparatus 
An acoustic startle system purchased from MED Associates (Fairfield, VT) was 
used for the fear conditioning, extinction, and potentiated acoustic startle 
testing. The acoustic startle system was comprised of four chambers and 
associated stimulus generators for light, shock and noise. All stimulus 
generators were controlled by a computer with purpose design software. Each 
melamine chamber (internal dimensions: 60 x 56 x 34 cm) was lined with sound 
attenuating acoustical foam which was 2.5 cm thick. During testing the subjects 
were enclosed in an animal holder (interior dimensions of cage: 16.5 x 8 x 9 cm) 
to restrict their movement. All four walls of the animal holder were made of 
horizontally placed steel bars (4.5 mm in diameter on floor, 2.5 mm in diameter 
on walls and roof, all spaced 15 mm apart). To reduce the likelihood of the 
animal damaging their head - cap during testing, wire mesh was placed over the 
bars on the roof and on the sides of the cage. The animal holding cage within 
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the chamber was mounted on MED associates’ accelerometer -based 
transducer platform (25 x 11.5 x 4.5 cm). The movement of the subject was 
translated into proportional variations in voltage output and was filtered and 
amplified before being measured by a MED Associates analogue-to-digital 
converter (ADC) card, a component of the computer that controls stimulus 
presentation. The house-light (#1820; 28 volt, 2.8 watt) and horn tweeter (6 cm) 
in each of the chambers was situated in the centre of the back wall. The startle 
stimulus was a 100 ms white noise burst, with a rise-decay time of 10 ms. The 
startle stimulus was produced by a MED Associates ANL 925 Programmable 
Audio Stimulator, amplified by an ANL 925A Audio Amplifier and presented 
through the horn tweeter in each chamber. Ambient noise in the chambers is 55 
dB as measured by a Simpson (model 860; Elgin, IL) sound level meter (A-
scale). All stimuli presentations were controlled by MED Associates software.    
 
Ambulatory activity was tested in a plexi - glass chamber (350mm width x 
380mm height x 337mm depth). The chamber was raised 20 mm above the 
ground and the base of the chamber is a stainless steel plate (330mm x 
320mm). Movement was measured via two sensors diagonally attached to the 
sides of the chamber. The sensors were positioned 200mm from the floor of the 
chamber. The movement measured by the sensors was controlled by an activity 
monitor (CFP 8181, Wiltons) and recorded on an electronic counter (Model 







5. 3. Procedure 
5. 3. 1. Surgery 
Pre - operatively, the subjects were given an intra - peritoneal injection of 
atropine (12mg/kg), this was prevent the accumulation of salivary and bronchial 
secretions during surgery. Thirty minutes later, rats were anaesthetised with a 
bodyweight injection sodium pentobarbitone (90mg/kg). They then received a 
subcutaneous injection of ketofen (10mg/ml) to the neck region,  this  served as 
an analgesic with anti-inflammatory properties. Prior to surgery the rats also 
received a 0.2ml injection of mepivacaine (20mg/ml) to the suture site, this 
acted as a local anaesthetic. The rats were then placed on a stereotaxic 
instrument (Stoelting, Wood Dale, IL) and bilaterally implanted with 22 – gauge 
stainless steel guide cannulae (C313G, Plastics One, Roanoake, VA). The 
cannulae were implanted on a 10° angle above the VTA, with the 
measurements from bregma, AP - 4.8, ML + 2.5, DV -7.5, and with 
measurements for the BLA from bregma, AP – 2.8 , ML + 4.8, DV – 8.2. The 
guide cannulae were be secured in place by four stainless steel jewellers’ 
screws (Lomat, Quebec, Canada) and dental cement. A recovery period of 
seven days elapsed post surgery and prior to the commencement of testing. 
 
5. 3. 2. Acoustic -  Startle  Screening  
Post surgery and prior to the fear - conditioning rats were tested for their 
individual acoustic - startle reflex. The acoustic - startle reflex was measured 
over two days, in test sessions consisting of three blocks of 10 noise 
presentations with a variable inter-stimulus-interval (ISI) of approximately 20s. 
On each day, animals were placed in the test chambers where they received a 
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5 minute acclimation period followed by a test session of 20 minutes. In the 
initial screening session all rats were exposed to white noise bursts of 95dB 
(100ms). Depending on the results of the first session the decibel level was then 
adjusted for each individual, to achieve the desired level of startle response. 
Although, the individual decibel level varied, the range was generally be 
between 90 and 100dB. 
 
5. 3. 3. Fear  Conditioning 
Following the selection of an appropriate decibel level, subjects were then  
given a session of fear - conditioning in the startle apparatus. Fear -  
conditioning was comprised of three sections; each section in turn consisted of 
10 pairings of the light (CS) and 600µA foot - shock (UCS). Thus, a total of 30  
pairings of the CS and the UCS were used to produce a Pavlovian - conditioned 
fear of the light stimulus. In this test design the ISI was fixed at 56s and the 
length of the stimulus presentations were 3500ms for the light presentation and 
250ms for the shock presentation. 
 
5. 3 .4. Group design 
Part a : Extinction & Infusion 
Group  N Implanted Drug Extinction 
Control II 7 VTA / BLA Saline (x3) Extinction 
Experimental I 10 VTA Amph. (x3) Extinction 
Experimental II 8 VTA Amph. (x3) No Extinction 






Part b: Psychomotor sensitisation 
Group N Implanted Pre. 
Infused 
I.P. injection Reason 
Control I  7 _____ _____ Saline Effect of injection stress and 
normal ambulatory activity 
Control II 7 VTA / BLA Saline Amph. Effect of amph. on ambulatory 
activity 
Control III 10 VTA Saline Amph No sensitisation 
Exptal I 10 VTA Amph. Amph. Sensitisation 
Exptal II 8 VTA Amph. Amph. Sensitisation 
Exptal III 7 BLA Amph. Amph.  Sensitisation – terminal vs. 
cell body 
 
5. 3. 5. Fear -  Potentiated  Startle  Test   
The subjects were placed in the startle chamber for a five minute acclimation 
period prior to the onset of the startle test. The test itself consisted of three 
different trial blocks. The first block was the presentation of 20 white noise 
bursts (100ms) with an inter-stimulus-interval (ISI) of 26 seconds. This block 
was used to establish the baseline acoustic startle reflex of the subject. The 
second block of trials were composed of 5 white noise presentations with a 26s 
ISI. This second series of noise alone presentations was used as a baseline 
comparison for the third and final series. The third block of trials is comprised of 
five pairings of a 100ms white noise burst and a 3500ms light (CS) 
presentation. The difference in acoustic startle reflex between the block of 5 
trials with noise alone and the trials with the noise paired with the light, was 




5. 3. 6. Infusion and  Extinction 
Following the  first fear - potentiated startle test, rats received either an intra-
VTA or an intra-BLA infusion of d-amphetamine or saline and extinction training. 
The dummy cannulae (C313DC, Plastics One) were removed and 28-gauge 
(0.36mm) stainless steel infusion needles (C3131, Plastics One) were inserted 
so that the tip of the needle protruded 1mm below the base of the guide 
cannulae. The infusion needles were attached via polyethylene tubing (PE20, 
Plastics One) to a 2 - µl Hamilton Syringe. The tube was preloaded with either 
physiological saline or d-amphetamine (2.5µg/0.5µl). The d-amphetamine 
(Sigma, Castle Hill, New South Wales, Australia) was dissolved in physiological 
saline mixture comprised of 2.5µg/0.5µl. Via the polyethylene tubing, the 
bilateral infusion of 0.5µl of either d-amphetamine or saline took 1 minute. A 
two-minute period after the infusion was allowed to elapse before the infusion 
needles were removed and the dummy cannulae were reinserted. The purpose 
of this two-minute period was to allow time for the drug to be absorbed into the 
designated area. Throughout the infusion the subjects were held lightly in a 
towel. 
 
Immediately after the replacement of the dummy cannulae the subjects were 
placed in the either the startle chambers or placed back in their home cages. 
For those placed in the startle chambers, they then received extinction trials. 
Following a five – minute acclimation period those receiving extinction were 
then presented three blocks of ten light presentations. In each of these blocks 
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5. 3. 7.  I. P.   Injection and Behavioural Sensitisation 
Animals were administered a 2 mg/kg dose of either d-amphetamine or 
physiological saline intra-peritoneally. The subjects were then placed in the 
locomotor chamber for an hour and their locomotor activity was be recorded in 
10 minute intervals.  
 
5. 4.  Histology 
At the end of testing subjects were overdosed with sodium pentobarbitone and 
perfused intra-cardially with saline, followed by Formalin (10%). The brains 
were then removed and stored in a Formalin (10%) solution for two days before 
being transferred to a 70% sucrose solution for several weeks. The brain were 
then frozen (-24˚) and coronal sections (50 µm) of the area of interest were 
sliced. These coronal sections were mounted on gel coated slides and stained 
with cresyl violet. The placement of the guide cannulae were then confirmed 
microscopically. One subject (A7) from  mixed control group II, two subjects (A5 
and A12) from the BLA/Amphetamine + Extinction group, and 1 animal (#54) 
from the VTA/Amphetamine + No Extinction group lost headcaps and did not 
complete testing. One subject (#24) from experimental group one VTA/ 
Amphetamine + Extinction, had incorrectly placed cannulae and was not 
included in the analysis. Cannulae placements of subjects included in the data 





5. 4. 1.   Placement verifications for Experimental Group I  



































A schematic depiction of guide cannulae locations for Experimental Group 1 – 
Amphetamine / VTA + Extinction  ( N = 10) Bilateral VTA implants, guide cannulae were 
implanted at a 10 ° angle, with the measurements from bregma, AP - 4.8, ML + 2.5, DV -









5.4.2. Placement verifications for Experimental Group II 
(Bilateral VTA implants) 
 
 
A schematic depiction of guide cannulae locations for Experimental Group 2 – 
Amphetamine / VTA + No Extinction (N = 8)Bilateral VTA implants, guide cannulae were 
implanted at a 10 ° angle, with the measurements from bregma, AP - 4.8, ML + 2.5, DV -










5. 4. 3.  Placement Verifications for Experimental Group III 
(Bilateral BLA implants) 
 
 
A schematic depiction of guide cannulae locations for Experimental Group 3 – 
Amphetamine / BLA + Extinction (N = 7) Bilateral BLA implants, guide cannulae were 
implanted at a 10 ° angle, with the measurements from bregma, AP - 2.8, ML + 4.8, DV - 
8.2,  aimed 1mm above BLA. Representative sections (Paxinos & Watson, 1998) 
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6 R E S U L T S  –  P A R T   A 
 
 
6. 1. Acoustic Startle and Selected Decibel Levels 
 
 
The acoustic startle levels of individual animals were not significantly different 
across groups during baseline screening sessions, F (4, 36) = 0.19, p = 0.94. 
Thus, any differences seen in startle levels following experimental 
manipulations were not the result of variable baseline levels.  Additionally, the 
decibel levels selected for each subject did not differ significantly between the 
experimental groups, F (4, 36) = 0.83, p = 0.51. The noise burst intensity to 
measure acoustic startle varied between 92 – 98 dB, with an average level of 
94. 85 dB. 
 
     
S E C T I O N   O N E :  Effect of Intra-VTA Amphetamine on Extinction 
 
 
Control Group 1: (Chronic saline infusions prior to extinction) 
 
Subjects who received three intracranial infusions of saline  served as a control 
group (Control Group 1, N = 7) for animals who received three intracranial 
infusions of amphetamine prior to extinction sessions. Within the group each 
subject served as its own control, providing an acoustic startle score for the 
FPS test ascertaining acquisition of conditioned fear, and following extinction 
sessions, for the FPS test ascertaining extinction of conditioned fear. A 2 TEST 
(acquisition / extinction) X 2 STIMULUS (Noise alone / Light + Noise) repeated 
measures showed a significant interaction between the two main factors, Test 
and Stimulus, F (1,6) = 7.78, p < 0.032, for the control group. There was no 
significant alteration in baseline acoustic startle responding throughout the 
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experimental procedure,  subjects showed consistent acoustic startle levels in 
the noise-alone component of both the initial and final fear test, F (1, 6) = 1.34, 
p = 0.29 . The control group acquired significant fear of the light following 
pavlovian fear -conditioning trials, F (1, 6) = 10.78, p< 0.02, and displayed 
augmented acoustic startle responses in the presence of the light on the initial 
fear test. However, after receiving three extinction sessions of 30 light alone 
presentations, with saline infusions prior to each one, the control subjects did 
not show significant fear of the light on the final fear test, F (1,6) = 0.61, p = 
0.47. These results demonstrate normal extinction learning, where the control 
subjects had effectively extinguished their previously acquired fear of the light, 
following the continued presentation of the light (CS)  without the corresponding 

























Fig.6.1.  Repeated- measures ANOVA results for subjects infused with saline (Control 
























Experimental Group 1: (Repeated intra-VTA amphetamine prior to extinction) 
 
Like control  subjects, the subjects in Group 1 showed consistent acoustic 
startle levels in the noise-alone component of both the acquisition and extinction 
fear test, F (1, 9) = 0.0003, p =0.99, meaning baseline - startle responding did 
not change during the course of the experiment. In this design animals served 
as their own control subjects for within group comparisons. A repeated 
measures ANOVA yielded a significant Test X Stimulus interaction, F (1,9) = 
7.22, p < 0.02.  Experimental subjects acquired conditioned fear, as measured 
with fear-potentiated startle, on the initial fear test following conditioning trials F 
(1, 9) = 64.5, p < 0.00002. Following three extinctions sessions, prior to which 
each animal was infused bilaterally with 2.5μg d-amphetamine intra-VTA, the 
subjects were tested again for conditioned fear. The animals showed that they 
had retained their previously conditioned fear  of the light, in spite of 90 
unreinforced presentations of the light over  three extinction sessions F (1, 9) = 
12.5, p < 0.006. Unlike the control subjects, the experimental group did not 
show normal extinction learning indicating that repeated intra-VTA 
administration of d-amphetamine, prior to extinction sessions, impairs  
















































Fig.6.1. Repeated- measures ANOVA results for repeated intra-VTA amphetamine 
subjects (Experimental Group 1, N = 10), FPS Test 1 & 2, both tests significant, p < 0.01**, 
p < 0.0001 ****. 
 
 
Experimental Group 1  vs. Control Subjects: (Repeated intra-VTA 
amphetamine prior to extinction vs. Repeated saline infusions prior to 
extinction) 
 
As the experimental manipulation occurred after the first fear test, during the 
extinction sessions, any evidence of a difference between the two groups would 
only be apparent on the final fear test.  It was hypothesised that there would be 
a significant difference between the group which received amphetamine 
infusions prior to extinction sessions and control subjects who received saline 
infusions. To assess the between group effects a 2 DRUG 
(saline/amphetamine) X 2 STIMULUS (Noise alone/ Light + Noise) ANOVA was 
conducted on the final fear test, showing a difference between the two groups 
Amphetamine + Extinction
Group



















on the final FPS test that was approaching significance, F ( 1, 15) = 4.22, p < 
0.058.  
 
                 
         
 
 
Fig.6.3. Repeated- Measures ANOVA between Repeated AMP-VTA + Extinction 
(Experimental 1) and Repeated Saline + Extinction (Control 1)on FPS Test 2. Difference 
between the groups approaching significance. 
 
 
A simple effects analysis showed no significant difference between the two 
groups noise – alone component, F (1, 15) = 0.15, p = 0.71, meaning that 
baseline acoustic startle responding was comparable for each group.  
Conversely, there was a significant main effect between the two groups for the 
light + noise component, F (1, 15) = 5.05, p < 0.04,  showing that the acoustic 
startle responses of the experimental subjects were significantly in excess of  
the startle levels exhibited by control subjects. Importantly, this difference was 
not the result of an initial variation in baseline between the two groups.  
                        
n.s. 
*
p = 0.058 























































Fig.6.4. Contrasted Stimulus effects. Noise alone and Light + Noise conditions on FPS 
Test 2, for AMP-VTA + Extinction (exp 1) and Sal + Extinction (con 1). One – way ANOVA 
for both groups on each Stimulus-Condition. 
 
 The overall analysis indicated a difference between the two groups that was 
approaching significance on the second fear test, closer analysis showed that 
the two groups were responding significantly different in the presence of the 
conditioned stimulus (light).  The experimental subjects were still showing 
significant fear of the light on the final fear test whereas the control subjects 
were not, with the controls showing normal extinction learning and the subjects 
who received amphetamine showing an extinction impairment. 
 
n.s. 




















S E C T I O N   T W O : Effect of Repeated Intra-VTA Amphetamine on the               
Expression of Pavlovian Conditioned Fear. 
 
This section examines whether the results seen in Section One of the study 
were the consequence of repeated d-amphetamine enhancing conditioned fear 
in subjects. To determine the effect of repeated intra-VTA amphetamine on the 
expression of Pavlovian conditioned fear,  a group of animals (Experimental 
Group 2, N = 8) received fear conditioning and were tested for fear-potentiated 
startle. Following the confirmation from the FPS test, that the subjects had 
acquired fear of the conditioned stimulus, they were infused 3 times with d-
amphetamine (2.5 µg bilaterally), with each infusion spaced 48 hours apart. The 
key difference between experimental group 2 and experimental group 1, is that 
after each infusion subjects in group 2 were returned to their home cages 
without extinction sessions. Consequently, the behaviour of the subjects in 
group 2 on the final fear test would indicate whether the repeated administration 
of amphetamine to the VTA was increasing the expression of pavlovian 
conditioned fear, thereby clarifying the extinction impairment seen in group 1.  
 
Once again animals served as their own controls for within group measures.  
A 2 TEST (acquisition/expression) X 2 STIMULUS (Noise alone/ Light + Noise) 
repeated –measures ANOVA showed no significant Test X Stimulus interaction, 
F (1, 7) = 2.99, p = 0.12. Subjects showed acquisition of Pavlovian conditioned 
fear, with significantly augmented acoustic startle responses in the presence of 
the light on the initial FPS test, F (1, 7) = 28.7, p < 0.001. Subjects still showed 
significant fear of the conditioned stimulus on the final fear test, F (1,7) = 6.05, p 
< 0.04, after the three amphetamine infusions.  Although, for both the first and 
second FPS tests subjects showed significant fear of the conditioned stimulus, 
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the magnitude of the augmentation of acoustic startle in the final fear test was 
somewhat smaller than the initial test. A similar outcome was also apparent in 
experimental group 1. The most likely explanation is that the 5 presentations of 
the unreinforced CS in the initial fear test slightly reduced the fear of the CS in 
subjects. However, the two groups still exhibited significantly enhance fear of 
the conditioned stimulus on the final fear test. Figure 2.1 below illustrates the 
stability of fear responding for Group Three across tests. The important point 
that is illustrated clearly in Figure 6.5., is that the amphetamine administration 
did not cause a significant increase in fear expression on the final fear test. 
Thus, the extinction impairment seen in group 1 cannot be attributed to 
repeated amphetamine enhancing fear expression in subjects.  
                 























Fig.6.5 Repeated- Measures ANOVA for within group effects for AMP-VTA + No extinction 
group (exp. 2) No significant difference between tests, both FPS tests show significant 
fear-induced elevations, F (1, 7) = 28.67, p < 0.0011**,  F (1, 7) = 6.05, p < 0.04*. 
Amphetamine + No Extinction
Group





















When compared to subjects who received extinction sessions, group 2 did not 
significantly differ from them in their acoustic startle responses on the final fear 
test. Baseline acoustic startle levels, in the noise-alone condition were similar 
across Groups 1 and  2, F (1, 16) = 0.24, p = 0.63. Interestingly, the 
augmentation of startle amplitudes  elicited by the light for both FPS tests, for 
both groups did not differ from one another, F (1, 16) = 0.19, p = 0.66. A 
repeated – measures ANOVA yielded no significant difference between the two 
groups on either the initial fear test, F (1, 16) = 0.24, p = 0.63, or the final fear 







Fig.6.6. Repeated-Measures ANOVA. Comparison of FPS Test 2 both AMP-VTA groups, 
extinction vs. no extinction. No significant difference between groups. p = 0.66. 
Interference of AMP with extinction




















It appears that  the responding of the two groups who received repeated  
amphetamine infusions, is similar irrespective of whether the subjects received 
extinction sessions. Furthermore as amphetamine is not enhancing the manner 
in which subjects express fear , it indicates that the extinction impairment is 






































S E C T I O N   T H R E E : Regional Dissociation of Repeated Intracranial 
d- amphetamine Administration on the Extinction of Conditioned Fear 
 
The basolateral amygdala (BLA) plays a critical role in the acquisition, 
expression, and extinction of Pavlovian conditioned fear in rats (Kellett & 
Kokkinidis, 2004; Lindgren, Gallagher, & Holland, 2003; Nader & LeDoux, 
1999). Pharmacological manipulation of the BLA NMDA receptors blocks both 
acquisition and extinction of conditioned fear (Lee & Kim, 1998; Maren, 
Aharonov, Stote, & Fanselow, 1996). Given the importance of the BLA in 
extinction learning we assessed the effect of repeated amphetamine infusion 
bilaterally into the BLA prior to extinction sessions. Again, subjects served as 
their own controls for within group measures, with a comparison of acoustic 
startle augmentation on the acquisition FPS test and the final fear test following 
3 extinction sessions. No significant Test X Stimulus Interaction for Group Four, 
was yielded by a 2 X 2 repeated –measures ANOVA, F (1, 6) = 5.04, p = 0.07. 
Subjects who received repeated intra-BLA amphetamine showed significantly 
increased startle in the presence of the conditioned stimulus in the initial FPS 
test as expected,  F (1,6) = 40.3, p < 0.001 , but displayed normal extinction in 
the final FPS test, with no  significant increase in startle in the presence of the 
light, F (1,6) = 2.20, p = 0.18. Figure 6.7. shows a comparison of the startle 





           
Fig.6.7. Intra-amygdaloid AMP + Extinction subjects (Experimental 3, N = 7). Repeated 
measures ANOVA for FPS test 1 and 2. 
 
 
Intra-amygdaloid subjects showed significant extinction effects and in this 
respect their responses were distinct from the subjects who received chronic 
amphetamine infusions. Unlike the intra-VTA subjects there was no significant 
difference between the responding of the control animals and the amygdala-
infused subjects on either the first fear test (F (1, 12) = 2.79, p = 0.12) or the 
second fear test, F (1, 12) = 0.99, p = 0.34, as shown in Figure 6.8. This 
suggests that there is a regional dissociation regarding the amphetamine 
induced impairment of extinction learning, with the extinction impairment 


































































Fig.6.8. Repeated-Measures ANOVA. Between group effects. No significant difference 
between groups, Exp 3, intra-BLA-AMP + Extinction and Sal + Extinction. p = 0.34, on 





Regional specificity of AMP effects
























6. 2.  Behavioural  Sensitisation 
 
SECTION ONE: Repeated Amphetamine Pre-treatment in VTA vs. 
Repeated Saline Pre-treatment in VTA. 
 
Repeated intra-cranial amphetamine infusions into the VTA produce  long-
lasting changes to the sensitivity of that region. A challenge presentation of 
amphetamine, either peripherally or intra – cranially, following the chronic 
administration of amphetamine results in heightened behavioural activity in the 
subject (Kalivas & Weber, 1988, Hooks & Jones, 1992, Cador & Bjijou, 1995). 
In this study the locomotor effects of a single challenge injection of d-
amphetamine (2mg/kg i.p.) were assessed, for subjects who had previously 
received three infusions intra-cranially, of either d-amphetamine (2.5 μg/side) or 
saline.  Locomotor activity was then recorded at 10 minute intervals for the hour 
following the i.p. challenge injection of amphetamine.  
 
Extra-cellular concentrations of dopamine and amphetamine have been found 
to peak  in the caudate putamen approximately 30 minutes after  peripheral 
administration of d-amphetamine(Kuczenski, Melega, Cho, & Segal, 1997). 
Therefore, it was hypothesised that differences between the  subjects 
previously infused with saline in the VTA, and those previously infused with 
amphetamine, would largely be apparent in the final 30 minutes of testing. As 
predicted a repeated – measures ANOVA on the final 3 time bins, namely the 
final 30 minutes yielded a difference between the saline infused subjects and 
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the amphetamine infused subjects that approached significance, F (2, 34) = 
3.17, p= 0.054. 
 
              

































Fig. 4.1. Group Means for final 30 minutes of locomotor activity following challenge 
injection of d-amphetamine Comparison of pre-treatment effects in VTA subjects. 
 
 
It is possible that the linear decay of activity levels seen in the Saline Pre-
treatment Group, illustrated in Figure 4.1 are consistent with the gradual decline 
in extra-cellular levels of amphetamine and dopamine as described by 
Kuczenski and colleagues (1997). Kuczenski and associates(1997) found that 
after maximal extra-cellular concentrations were reached at 30 minutes a 
gradual decline in dopamine and amphetamine concentrations occurred with a 
half life of around 45 minutes. Increases in extra-cellular dopamine and the 
increases in locomotor activity seen following amphetamine administration 
share very similar temporal profiles to one another (Hertel et al., 1996).The 
behavioural responses displayed by the Saline Pre-treatment Group appear to 
exhibit similar a similar profile, with a behavioural peak at 30 minutes and a 
gradual decline beginning at 45 minutes. In contrast, the Amphetamine Pre-
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treatment Group did not show the gradual decline over the final 30 minutes of 
the test, rather this group  displayed a high level of responding.  Our findings 
are consistent with previous findings of others (Kalivas & Weber, 1988, Hooks & 
Jones, 1992, Cador & Bjijou, 1995), that repeated administration of 
amphetamine into the VTA, produces enhanced locomotor activity to a 
challenge injection. In relation to the extinction deficit seen in the first half of the 
study, the presence of sensitisation, suggests one possible underlying neural 
alteration to account for the impairment. It illustrates one important difference 
between the group that showed the extinction deficit and the group that did not, 
the group that had the extinction deficit also showed peripheral evidence of a 































SECTION TWO: Amphetamine vs. Saline Pre-treatment in the BLA  
 
Three amphetamine infusions into the BLA did not produce any sensitising 
effects to a subsequent systemic injection of amphetamine. Subjects previously 
administered amphetamine showed similar behavioural responding to the 
amphetamine challenge as did those who had previously been infused with 
saline in the BLA, F (5,45) = 0.81, p = 0.55.  Even in the final 30 minutes of 
recording, where evidence would be expected to be seen, a repeated – 
measures ANOVA yielded no significant difference between the two pre-
treatment groups, F (2, 18) = 0.20, p = 0.82, as shown in Figure 4.2. This lack of  
behavioural sensitisation seen in the BLA –amphetamine group, further 
supports the notion that  sensitisation of the VTA may be critical for the 
extinction deficit seen in the VTA – amphetamine group but not seen in the BLA 
– amphetamine group.  






























G1 - Amyg + Sal
pretreatment
G2 - Amyg + Amp
pretreatment
         
Fig.4.2. Final 30 minutes: Comparison of Pretreatment effects on BLA subjects during 
behavioural sensitisation test. 
30-40 40-50 50-60 
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SECTION THREE : Effect of Extinction Training on the Expression   of 
Behavioural Sensitisation in the VTA  
 
Like the group of subjects who received repeated amphetamine in the VTA and 
extinction training, the group that did not receive extinction training showed a 
different pattern of responding from the saline treated controls in the final 30 
minutes, and although not statistically significant, the result approached 
significance, F ( 2,30) = 2.83, p = 0.07. There was no overall difference in 
behavioural responses to the challenge injection, between groups that showed 
extinction in Part A of the study and groups that did not acquire extinction, 
F(5,190) = 0.87, p = 0.50. Extinction training itself, did not have any influence on 
the behavioural responses to the challenge injection, with no significant 
difference between groups that received extinction training and groups that did 
not, F (5,190) = 0.67, p = 0.65. 



































Fig.4.3. Final 30 minutes VTA-Amphetamine + No Extinction Group vs. VTA Saline 
Controls, F (2,30) = 2.83, p = 0.07. 
30-40 40-50 50-60 
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7 G e n e r a l   D i s c u s s i o n 
 
7. 1.  Synopsis 
 
Extinction occurs when the continued presentation of the CS, without the 
corresponding UCS, fails to elicit the CR. In this study the measured CR was 
the augmentation of the acoustic startle reflex. The augmentation of the startle 
reflex in the presence of the CS was interpreted as a quantifiable measure of 
the motivational state of fear. The strength of the fear-potentiated-startle 
response was taken, relative to the subjects’ baseline acoustic startle response, 
to be indicative of the level of fear elicited by the CS. Extinction training involves 
the continued unpaired presentation of the CS and is expected to minimise or 
eliminate the fear-arousing properties of the CS. Subject’s who received 
infusions of d-amphetamine (2.5 µg / 0.5µl) bilaterally into the VTA, prior to the 
extinction sessions failed to show significant attenuation of their conditioned 
fear of the light on a subsequent fear test. Although, the fear-potentiated startle 
exhibited by this group of subjects on the second fear test was of a smaller 
magnitude than that educed by the first test, nevertheless the fear-potentiated 
startle exhibited in the presence of the CS was still significantly greater than 
baseline acoustic startle.  These results can be interpreted to suggest that 
amphetamine reinforced fear responding during CS presentations, this in turn, 
produced a measurable resistance to extinction.  
The possibility that the extinction deficit was produced by a simple 
enhancement of fear expression as a result of chronic amphetamine infusions 
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was also addressed by this study.  The group of subjects that received chronic 
amphetamine without extinction, showed significant fear-potentiated startle on 
both  fear tests. If amphetamine was enhancing the expression of fear, it could 
be reasonably assumed that the fear-potentiated startle exhibited on the second 
test would be greater than that expressed on the first test. Subject’s that 
received chronic amphetamine infusions did not show greater fear-potentiated 
startle on the final fear test, indicating that prolonged administration of 
amphetamine did not significantly alter  fear responding to the conditioned 
stimulus. Interestingly, there was no significant difference between the 
responses of this group on the final fear test and the responses of the group 
who received amphetamine and three extinction sessions, further strengthening 
the suggestion that amphetamine administration is causing an extinction deficit. 
 
As the chronic administration of amphetamine is not enhancing the pre-existing 
levels of conditioned fear elicited by the CS, amphetamine administration alone 
is not responsible for the persistent fear seen in subjects who received both 
amphetamine infusions and extinction sessions. To recapitulate, the only 
difference between the two groups who received chronic amphetamine 
treatment was that the first group received three extinction sessions post 
infusions whereas the second group received no extinction sessions. The 
outcome was the same for both groups – significant fear on the final fear test – 
despite the different treatment conditions. As the only manipulated variable 
between the groups was the administration of extinction sessions to the first 
group, it would seem reasonable to assume that in some way the administration 
of amphetamine was impairing the efficacy of the extinction sessions.   
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The basolateral amygdala is an important region involved in altering the 
motivational significance held by a particular stimulus, this region has also been 
implicated in extinction learning (Kellett & Kokkinidis, 2004; Lindgren, Gallagher, 
& Holland, 2003) In this study, in contrast to the VTA, subject’s that  received 
amphetamine infusions prior to each of the three extinction sessions showed 
normal extinction learning. These results indicate that amygdala dopamine is 
not important in extinction learning. Although the amygdala is a major recipient 
of the efferent dopaminergic projections of the VTA, it is not the only region 
innervated by the VTA. The mesocortical projection from the VTA to the 
infralimbic cortex may prove an important projection for extinction. This 
suggestion is based on the findings of Quirk and colleagues (Lebron, Milad, & 
Quirk, 2004; Santini, Ge, Pena de Oritz, & Quirk, 2004) showing the importance 
of the medial prefrontal cortex (mPFC) and its’ projections to the amygdala in 
extinction learning. Interestingly, the amygdala is known to modulate the 
utilization of DA in the mPFC (Goldstein, Rasmusson, Bunney, & Roth, 1996),  
and it will be interesting to see the developments from future research  clarifying  
the relationship between the amygdala, the VTA and the mPFC  during 
extinction learning.  
 
The second part of this study explored the phenomenon of behavioural 
sensitisation to amphetamine. Overall subjects pre-treated with three injections 
of amphetamine (2.5µg/0.5µl/side) into the VTA showed no significant 
difference in behavioural responding to subjects pre-treated with saline, when 
given an i.p. challenge of amphetamine (2mg/kg). However, closer examination 
of the data revealed a difference between the two groups in the final thirty 
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minutes approached statistical significance. This was consistent with the 
literature which suggests maximal extra-cellular concentrations of both 
amphetamine and dopamine peak at 30 minutes after the systemic 
administration of amphetamine ((Kuczenski, Melega, Cho, & Segal, 1997). 
Extra-cellular dopamine levels and increases in locomotor activity , share 
remarkably similar temporal profiles (Hertel et al., 1996). Extra-cellular 
dopamine and amphetamine have a half-life profile of about 45 minutes 
(Kuczenski et al., 1997) and the majority of the effects of behavioural 
sensitisation are seen within the first 50 minutes after the administration of a 
systemic amphetamine challenge (Kalivas & Weber, 1988). It was therefore 
anticipated, that the saline pre-treated animals would show a slowing of 
behavioural responding in the final 30 minutes whereas the amphetamine pre-
treated subjects should show a heightened response to the locomotor-activating 
effects of amphetamine during those final 30 minutes. This hypothesis bore out, 
with saline pre-treated subjects showing maximal levels of activity at thirty 
minutes and then gradually waning over the following half hour. By contrast the 
amphetamine pre-treated subjects showed no such decline over the final 30 
minutes and consistently showed higher levels of responding than their saline 














7. 2.  Possible Explanations 
 
Is the repeated administration of amphetamine simply causing a learning 
impairment ? 
 
7. 2. 1     Extinction and the learning of a non-association 
In our study we found that subjects who received repeated amphetamine 
infusions prior to extinction sessions maintained significant fear  of the 
conditioned stimulus on an ensuing FPS test. Expressed in another way those 
subjects who received chronic amphetamine infusions did not display extinction 
on the final fear test. The interpretation of the subjects continued fear or non-
extinction, depends in part on the chosen definition of extinction. Rescorla  
(1969) expounds that through learning a stimulus acquires the properties of a 
conditioned inhibitor, as it  comes to elicit the opposite response from the 
subject as the conditioned excitor. If extinction is viewed as such it is a learned 
association, i.e. ; the subject learns to replace the conditioned association of CS 
– UCS, with a new pairing of CS – No UCS. Specifically in our study, extinction 
learning requires the acquisition of  a Light – No shock association.  
 
Traditionally amphetamine has been viewed as a pharmacological facilitator of 
learning. Systemic administration of methamphetamine prior to discrimination 
tests – tasks which require the acquisition and application of a designated 
concept – decreased the time required by subjects to learn an association 
(Rahmann, 1970). If amphetamine was facilitating the speed at which subjects 
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learned the new CS – No US association, then the anticipated result would 
have been a rapidly acquired extinction of the conditioned fear. As the subjects 
who received amphetamine prior to the extinction sessions did not show 
enhanced acquisition of the extinction association it appears that the application 
of intracranial amphetamine is not exerting its’ effect by facilitating associative 
learning.  Rather, our results suggest that amphetamine-induced VTA activity is 
impairing extinction learning. Interestingly, although the BLA has been 
implicated as a critical region for extinction learning (Kellett & Kokkinidis, 2004) 
we did not find that dopaminergic manipulation of the BLA resulted in any 
impairment to the subject’s ability to learn an extinction association. 
 
7. 2. 2. Learning conceptualised as synaptic plasticity:  Long-term 
potentiation, learning and memory 
 
Extinction learning can be conceptualised as the acquisition of a new inhibitory 
association to replace a pre-existing excitatory association. Viewed in this light 
extinction can also be seen as alterations on a synaptic level to the strength of 
the initially conditioned association. Long-term potentiation (LTP) is a form of 
glutamatergic synaptic plasticity, that has been postulated to be the neuronal 
substrate of learning and memory in fore-brain regions (Jones & Bonci, 2005; 
Kauer, 2004; Malenka & Nicoll, 1999). LTP is a persistent increase  in excitatory 
synaptic transmission and the opposing process that down-regulates synaptic 
strength is referred to as long-term depression (LTD) (Bear & Abraham, 1996). 
The increase in synaptic transmission as a result of LTP, means that the test 
stimulus involved in the acquisition of LTP, when applied after the induction of 
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LTP, will elicit a  significantly larger response than had previously been evoked. 
The consistent  production of LTP in areas such as the hippocampus, known to 
be heavily involved in learning and memory, has given support to the 
proposition that this form of glutamatergic synaptic plasticity could be the 
neuronal substrate of learning and memory (Malenka & Nicoll, 1999). 
 
7. 2. 3. Biochemistry of Long-term potentiation 
 
The biochemistry of LTP has been extensively studied and although many of 
the precise mechanisms are still uncertain, there is general consensus about 
the basic processes involved in the induction of LTP. For review see (Jones & 
Bonci, 2005; Kauer, 2004; Malenka & Nicoll, 1999; Wolf, Sun, Mangiavacchi, & 
Chao, 2004).  The release of the excitatory neurotransmitter glutamate, during 
normal synaptic transmission, acts on post-synaptic AMPA and NMDA 
receptors. The AMPA receptor is permeable to both sodium (Na+) and 
potassium (K +). When the cell is close to its’ resting membrane potential, the 
AMPA receptor provides the majority of the inward current. Under the normal 
parameters of synaptic transmission the NMDA receptor contributes very little to 
the inward current received by the post-synaptic cell. This inaction is largely due 
to the extra-cellular blockade of the NMDA receptor channel by magnesium 
(Mg2+). The induction of LTP requires the depolarisation of the post-synaptic 
cell. The depolarisation of the cell causes the  Mg2+ to dissociate itself from the 
NMDA receptor channel and allows the flow of Na+ and Ca2+ into the post-
synaptic cell. The intracellular rise of Ca2+ in the post-synaptic cell is the 
necessary catalyst for LTP to occur. The generation of LTP is input – specific, 
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more precisely, the repeated activation of a synapse on a particular cell does 
not strengthen all synaptic connections on that cell. Although LTP is normally 
input - specific, strong activation of a synapse can also strengthen adjacent 
synaptic connections. The associative strengthening of synaptic connections 
during LTP has been used as a model to explain the neural substrate of 
classical conditioning. The CS gains associative synaptic strength through its’ 
temporally proximate activation with the UCS. 
. 
7. 2. 4. VTA, Psychomotor Stimulants, LTP and LTD 
 
7. 2. 5. LTP & LTD 
 
A single systemic injection of cocaine is sufficient to induce LTP in the 
dopaminergic neurons of the VTA (Ungless, Whistler, Malenka, & Bonci, 2001). 
Mice injected with a single dose of cocaine, showed a larger AMPA / NMDA 
receptor ratio than saline injected controls, indicating the occurrence of LTP in 
cocaine pre-treated controls. Additionally, Ungless and colleagues (2001) found 
that the single exposure of cocaine was sufficient to induce context-dependent 
behavioural sensitisation. The behavioural sensitisation was attenuated by the 
local administration of MK-801 (NMDA receptor antagonist ) into the VTA, as 
was the change in AMPA/NMDA  receptor ratio induced by cocaine. The 
blockade of both behavioural sensitisation and LTP by the administration of 
NMDA receptor antagonist, MK-801, indicates that both psychomotor induced 
LTP and behavioural sensitisation are NMDA dependent in the VTA. 
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The induction of LTP in the VTA appears to be a process common to drugs of 
abuse. Saal and colleagues (2003) extended the findings of Ungless and co-
workers(2001)  to include other drugs of abuse such as  amphetamine, 
morphine, ethanol and nicotine. They found that this cohort of drugs all caused 
the same increase in AMPA/ NMDA ratio at excitatory synapses in midbrain DA 
cells. Interestingly, the effects of acute stress, using a forced swim task, 
resulted in an AMPA/NMDA ratio that was even larger than that of the drugs of 
abuse. Potentially, in this study there could have been a cumulative effect of 
amphetamine and stress causing a greatly increased ratio of AMPAR/NMDAR 
at  the excitatory synapses in the VTA.  
In vitro  induction of LTD in the VTA has also been demonstrated (Jones, 
Kornblum, & Kauer, 2000; Thomas, Malenka, & Bonci, 2000). Unlike LTP in the 
VTA it is not dependent on the activation of NMDA receptors and is triggered by 
non-L type voltage-dependent calcium channel activation. Interestingly, VTA 
slices, bathed in amphetamine, showed inhibition of electrically induced LTD 
(Jones et al., 2000). The effect of psychomotor stimulants on LTD In vitro, 
appears to translate to in vivo studies. Ungless and colleagues (2001)  
observed greater LTD in cocaine pre-treated animals. This finding was 








7. 2. 6.         Possible Explanations arising from LTP/LTD 
 
7. 2. 7. LTP  vs. LTD:   Blockade of  LTD 
 
LTP and LTD have been proposed to be counter- balancing mechanisms whose 
net strength governs regional functioning(Bear & Abraham, 1996)  . LTP is 
thought to be the underlying neuronal mechanism responsible for  the plasticity 
involved in responding to new stimuli. Conversely, LTD is the neuronal 
mechanism involved in losing responsiveness to previously effective stimuli. 
These two opposing processes appear conceptually to be governing different 
aspects of learning. LTP seems to be the process necessary to the acquisition 
of an association, whereas LTD seems to be required  for the extinction of a 
previously acquired association. One way to test the validity of this hypothesis 
and assess the relative contributions of LTP and LTD to learning is to 
selectively block one type of plasticity and compare performance on a learning 
task with untreated controls. Effectively, the study has done just this. 
Amphetamine administered to the dopaminergic neurons of the VTA is known to 
block  LTD(Jones et al., 2000). The unrestrained contribution of LTP in an 
inhibitory learning situation, like extinction, may be the cause of the extinction 







7.3. Functional consequences of LTP 
 
7. 3. 1. Increased motivational significance of the CS 
 
The functional result of psychomotor stimulant induced  LTP in the VTA, is the 
enhancement of DA transmission  to terminal fields (i.e. cortical areas and other 
limbic structures) (Wolf et al., 2004)  . This enhancement of DA transmission, 
due to LTP, is assumed to persist days after the last administration of the drug. 
In this state of increased dopaminergic transmission cues associated with the 
drug attain greater motivational significance(Schultz, 2002). Perhaps,  in this 
study as the CS (light) was continually paired-with the drug state, that the cue 
later encountered in an LTP altered state had acquired greater motivational 
(fear-inducing) properties. However, such an explanation rests on the premise 
that the administration of amphetamine intracranially, had discernable 
physiological properties for the subject. The literature surrounding the self-
administration of psychomotor stimulants to the VTA (Koob & Bloom, 1988) 
provides support that the intracranial administration of amphetamine to the VTA 
does have discernable physiologic consequences for the subject.    
 
7. 3. 2.  Medial-Pre-Frontal-Cortex and DA transmission  
Increased DA transmission in cortical areas, as the result of psychostimulant 
induced LTP in the VTA raises another possibility MPFC feedback influencing 
the amygdala. Excitation of MPFC neural activity inhibits amygdaloid functioning 
and influences extinction (Quirk, Likhtik, Pelletier, & Pare, 2003). MPFC DA 
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may have an inhibitory influence on MPFC neural activity and this inhibition may 
underlie the extinction deficit observed in the present study. 
 
 
7. 4. Are the neurochemical actions of amphetamine  somehow 
impairing the extinction of conditioned fear?  
 
7. 4. 1.  Effect of amphetamine on dopamine   
The acute and immediate effect of systemic amphetamine administration is to 
increase extracellular dopamine (Bunney & Aghajanian, 1973). Extra-cellular 
levels  of dopamine peak immediately after amphetamine administration but this 
effect is short-lived, and the overall effect produced by continued amphetamine 
administration is a decline in basal dopamine levels (Imperato et al., 1996).  
The specific mechanisms employed by amphetamine on a cellular level are still 
relatively uncertain. The increased release of dopamine by amphetamine 
appears to be caused by the redistribution of dopamine to the cytosol. Leading 
to a single and significantly increased release of DA from amphetamine treated 
neurons (Sulzer et al., 1995).The depletion of vesicular stores and the 
increased initial expulsion of dopamine from the amphetamine treated neuron 
occurs via reverse transport.  
 
7. 4. 2. DA receptor regulation 
 
AMP iontophoretically administered directly to DA cells causes very little change 
to the firing rate of the DA neuron itself, the administration of AMP to  
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postsynaptic neurons in the same region causes a marked depression of firing 
rates(Aghajanian & Bunney, 1973). It has been suggested that a feedback 
pathway is mediating the depressant effects of AMP on DA neurons, rather than 
a direct post-synaptic action of the drug (Bunney & Aghajanian, 1973). 
 
More recently, the psychomotor stimulant has been found to affect the 
dopaminergic neurons of the CNS in both an excitatory and inhibitory manner 
(Shi, Pun, Zhang, Jones, & Bunney, 2000). Under basal conditions dopamine 
release is primarily inhibited via the local D2 receptor. Under conditions where 
the extracellular level of dopamine has been significantly raised, such as 
following the application of AMP, the concurrent activation of both D1 and D2 
receptors is necessary to inhibit the DA neuron (Adell & Artigas, 2004; Shi, 
2000).   
 
Interestingly, the successful blockade of the inhibitory effects of the D2 receptor 
with raclopride, following the administration of amphetamine, led to the 
discovery that the excitatory effects of AMP administration are non-DA 
mediated (Shi et al., 2000).  Amphetamine therefore appears to have dual 









7. 4 . 3.  Differences between somatodendritic and terminal release of 
DA  
The administration of amphetamine causes the release of DA in the midbrain 
region,  consequently, DA is released from not only the nerve terminals, but 
also from the cell body and its proximal dendrites(Cragg & Greenfield, 1997; 
Geffen, 1976; Korf, Zieleman, & Wseterink, 1976). The subsequent exodus of 
DA from the neuron activates both long-loop feed back mechanisms and 
autoreceptors which combine to inhibit the firing of the neuron(Bunney, Walters, 
Roth, & Aghajanian, 1973; Shi, 2000). Both the release and feedback inhibition 
of DA differ between somatodendritic and axon terminal regions. Quantitatively, 
DA released from the axon terminals is consistently greater than the that 
released in the somatodendritic regions(Cragg & Greenfield, 1997). During 
normal DA function, uptake by the DA transporter (DAT) is less efficient in 
somatodendritic areas than in terminal regions (Adell & Artigas, 2004; Cragg, 
Rice, & Greenfield, 1997; Geffen, 1976). This function is consistent with the 
larger number of DA uptake sites in terminal areas. As a result of the varying 
degrees of uptake efficiency a different time course of action exists for 
somatodendritic DA release and terminal DA release. The differences between 
the somatodendritic release of DA and the axon terminal release of dopamine 
also include variation in autoreceptor regulation (Cragg & Greenfield, 1997). 
The differences in the regulation of extracellular dopamine appear to be 
dependent upon location, autoreceptor regulation and the presence of DAT. 
Approximately, 95% of intracellular DAT in VTA dopaminergic neurons is 
located within the perikaya and it’s immediate dendrites. The remaining 5% of 
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DAT is found within the unmyelinated axons of the cell(Nirenberg et al., 1997). 
Potentially the disparate results seen in the non-extinction of subjects who 
received amphetamine chronically into the VTA, and the extinction of those 
subjects who received amphetamine into the BLA, could be due to the 
underlying differences in the regulation of extracellular dopamine in the two 
different regions. The discrepancy could be explained as a difference in the 
regulation of extracellular dopamine in terminal regions compared to 
somatodendritic regions.  
 
7. 4 . 4. Dopamine release and neurochemical control 
The firing rate of the DA neuron can act as an error signal for the prediction of 
reinforcement. When an anticipated event does not occur, dopamine firing rates 
decrease. Dopamine therefore is signalling the quality of the environment as a 
predictor of the anticipated event. For review (Schultz, 2002). During extinction 
sessions in normal circumstances, dopamine would act as an error signal. The 
firing rates of the dopamine cell would be expected to decrease as the CS 
(light) becomes a consistently poorer predictor of the shock (UCS). The 
administration of amphetamine  immediately prior to  extinction sessions will 
cause an immediate increase in extra-cellular dopamine, followed by inhibition 
of the firing rate of the dopamine neuron. The pharmacological manipulation 
used in this study may have  affected the ability of dopamine to function as an 
effective error signal.  The resultant decrease in dopamine firing rates that 
would under normal circumstances accompany the weakening of the CS as a 
predictor of the UCS, had already been pharmacologically instigated prior to the 
presentation of the unpaired UCS. Conversely, the immediate increase in extra-
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cellular dopamine post infusion may mean an overly active error signal. 
However, if the pharmacological interference  is creating an error signalling 
deficit, then the extinction deficit should have been seen in both the group 
receiving infusions into the amygdala and the subjects receiving infusions into 
the VTA. As the two groups did not show identical results, it suggests that the 
underlying mechanism is more complex than a deficit in neurochemical error 
signalling.  
 
7. 5. Is the extinction impairment the result of an amphetamine effect on 
memory?  
 
Historically, the systemic administration of amphetamine has been linked to 
improvements in memory – related tasks(Carr & White, 1984; Doty & Doty, 
1966; Rahmann, 1970). The enhancement produced by amphetamine on 
memory-related tasks is both dependent upon dose and temporal proximity. 
Low doses of methamphetamine prior to testing were found to decrease subject 
learning latency in discrimination tasks and also significantly prolonged subject 
retention (long-term memory) of the correct responses to these tasks 
(Rahmann, 1970). Amphetamine administered post training also facilitates the 
consolidation of memory. This is a temporally constrained effect with facilitation 
found when amphetamine is administered at proximal but not distal intervals 
following training (Doty & Doty, 1966).                                                                                             
 
Carr and colleagues (1984) found that a post-training injection, either 
systemically of intracranially facilitated the consolidation of recently formed 
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associations. Additionally they found a significant correlation between 
stereotypic behaviour and memory retention i.e. subjects who showed the 
greatest amount of stereotyped behaviours following the administration of 
amphetamine also showed the strongest  conditioned suppression when tested 
48 hours later. The enhancement of memory seen here was retroactive, insofar 
as the subjects received amphetamine immediately after to the conditioned 
suppression training. Those who received amphetamine immediately after the 
training showed greater suppression than those who received delayed 
administration of amphetamine, indicating a transient window for facilitation of a 
previously learned association.  
 
Interestingly, the neurotransmitter NMDA also seems to exert a transient effect 
on memory consolidation (Santini, Muller, & Quirk, 2001). Systemic 
administration of NMDA receptor blocker CPP prior to extinction learning did not 
interfere with acquisition of extinction 1 hour after extinction nor did it at 
48hours, however an extinction impairment was displayed by subjects 24hours 
after extinction learning. This study highlights the importance of considering the 
temporal elements involved in the consolidation of extinction learning, especially 
when the pharmacologically  manipulating extinction learning. The extinction 
impairment seen in this study may have been due to some interaction between 
the  temporal aspects of extinction consolidation and amphetamine itself. 
 
Extinction of a response is not due to the ‘forgetting’ of the conditioned 
association over the course of time. Fear related behaviours present in a 
conditioned – fear paradigm, will persist across large time periods (McAllister, 
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McAllister, Scoles, & Hampton, 1986) and also show considerable tenacity as 
exemplified by phenomena such as spontaneous recovery and renewal. Given 
the longevity of the conditioned fear association and the transient nature of 
neurochemical correlates with the facilitation of previously learned associations,  
the administration of amphetamine immediately prior to extinction sessions, 
may have been retroactively enhancing the CS-UCS association learned in that 
context. 
 
7. 6. Behavioural Sensitisation  
 
Primarily the in vivo, intracranial induction of amphetamine sensitisation has 
focused on the dopaminergic projection from the VTA to the nucleus 
accumbens (mesoaccumbens pathway), a pathway largely involved in the acute 
locomotor effects of amphetamine administration (Cador, Bjijou, & Stinus, 1995; 
Hooks, Jones, Liem, & Justice, 1992; Perugini & Vezina, 1994; Vezina, 1993; 
Vezina & Stewart, 1990). Rats who received three infusions of amphetamine 
(3µg/0.5µl) into the nucleus accumbens (NACC) did not show significant 
augmentation of  behavioural responding to a challenge i.p. injection of 
amphetamine (1mg/kg) compared to  control subjects. This regimen acutely 
produced a significant increase in ambulatory activity, but chronically did not 
induce behavioural sensitisation (Hooks et al., 1992) in the NACC. Conversely,  
the same chronic treatment in the VTA induced behavioural sensitisation to a 
challenge injection of amphetamine  (Hooks et al., 1992; Kalivas & Weber, 
1988; Vezina & Stewart, 1990), while  an acute infusion of amphetamine into 
the VTA did not increase locomotor activity in subjects (Kalivas & Weber, 1988). 
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These findings emphasise the distinct contribution of each  neural region to the 
phenomenon of amphetamine-induced behavioural sensitisation.   
 
Intracranial induction of behavioural sensitisation is not only region specific, but 
is also dose dependent. A foundational study by Kalivas and Weber (1988) 
showed that  two infusions of 1.5 µg/µl amphetamine intra-VTA were sufficient 
to produce significantly enhanced locomotor effects to an  i.p. challenge 
injection (1.0mg/kg). While others have failed to achieve sensitisation at such 
low doses(Cador et al., 1995), the most consistently used dose is 2.5 
µg/µl(Cador et al., 1995; Perugini & Vezina, 1994; Vezina, 1993; Vezina & 
Stewart, 1990). Subsequent studies found that the intra-VTA injections of 
amphetamine cross-sensitised subjects to other drugs of abuse such as 
morphine (Vezina & Stewart, 1990), and cocaine (Hooks et al., 1992). 
Additionally, behavioural sensitization can also be elicited by an intra-cranial 
challenge injection (Cador et al., 1995; Perugini & Vezina, 1994) of 
amphetamine to the nucleus accumbens. Controversy, remains about the 
generalisabilty of the intracranial induction of behavioural sensitisation via 
amphetamine to the entire class of psychostimulants. Four infusions of cocaine 
into the VTA, at a variety of dosages did not produce enhanced locomotor 
activity to systemic challenge of cocaine. This result could not be ascribed  to 
the anaesthetic effects of cocaine as WIN 35, 065-2 (cocaine analogue without 
anaesthetic properties) did not produce sensitization either (Steketee, 1998). 
However, Cornish and Kalivas(2001) were subsequently able to produce 




The subjects  in this study, consistent with the literature did show behavioural 
sensitisation to the amphetamine challenge, following repeated intra-VTA 
amphetamine (2.5 µg/0.5µl). This effect within the context of this study primarily 
helped to confirm that the subjects had in fact been successfully receiving 
amphetamine to the VTA during the fear extinction trials. Additionally, the 
extinction  impairment seen in the behaviourally sensitised subjects allows the 
possibility that the  neurochemical basis of one could underlie the other. More 
specifically it raises the possibility  that the neurochemical basis of the extinction 
impairment is a sensitised mid-brain dopaminergic projection. 
 
7. 7. Possible Confounds 
 
7. 7. 1. The problem of state dependency  
 
Fear extinguished in a drug state, may be renewed when the subject is placed 
back in the context, in  a non-drug state and tested (Bouton, 1993). This tenet, 
known as state - dependency , is a potentially confounding factor in a study of 
this nature. Bouton and colleagues (1990) found state – dependent retention of 
extinction in subjects treated with benzodiazepines. The subjects displayed 
successful acquisition of extinction whilst under the influence of the drugs, but 
failed to show extinction when tested in the non-drug state. This state –
dependent retention of extinction has been shown with a variety of drugs 
including  pentobarbital, amobarbital and alcohol(Barry, Etheredge, & Miller, 
1965; Cunningham, 1979; Overton, 1964). With regard to this study, the 
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possibility that the extinction impairment is due to a failed transfer of learning 
from the drug state to the non-drug state, is a potential confound. State-
dependency in this paradigm necessarily rests on the assumption, that 
extinction was acquired in the drug state and subsequently forgotten in the non- 
drug state.  The group that received amphetamine infusions into the amygdala 
showed normal extinction learning. This result throws into doubt any question of 
state dependency, as the amygdala subjects successfully transferred extinction 
learning from the drug state to the final fear test, which was in a non-drug 
context. 
 
7. 7. 2. Introduction of a novel stimulus 
Another possibly confounding factor that would benefit from further explanation 
is whether the introduction of the novel amphetamine prior to extinction 
produces an extinction deficit  simply because it acts as a novel disruptor. This 
presupposes that the intra-cranial administration of amphetamine is a 
discernable physiologic to the subject. Intra-cranial self-administration studies 
support the idea that the intra-cranial infusion is a discernable physiologic event 
to the subject.  Animals will self administer a large variety of drugs of abuse 
directly to the VTA, including morphine, ethanol (for review see(McBride, 
Murphy, & Ikemoto, 1999), suggesting that the effects of drugs administered 
intra-cranially are discernable to the subject. A potential way that this problem, 
of the introduction of a novel stimulus, could be countered would be to have a 
group who received amphetamine infusions prior fear conditioning, to determine 
whether the introduction of amphetamine interfered with the acquisition of an 
association. However, once again the fact that the group who received 
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amphetamine infusions into the basolateral amygdala prior to extinction showed 
the successful acquisition of extinction, brings into to question the necessity of 
repudiating the novel-disruptor problem. 
 
7. 8. Discussion and Future Extensions 
 
The results of this study have interesting implications for our understanding of 
fear, psychosis and schizophrenia in general. As normal fear is characterised by 
an adaptive response to an aversive or dangerous situation, abnormal fear can 
be characterised by defensive behavioural response in the absence of an 
immediate or future threat. Persistent  fear of an innocuous stimulus can lead to 
the development of phobias and paranoid psychoses. As, such this type of fear 
can be conceptualised as an extinction impairment on the part of the individual. 
Whether this impairment is the result of a neurochemical imbalance or the 
consequence of a learning deficit, namely the inability of the subject to acquire 
extinction associations, it is of importance to understand the processes 
underlying this persistent fear, to better develop ways of treating it. 
Subjects who received repeated infusions of amphetamine into the VTA prior to 
extinction sessions showed an extinction impairment on a subsequent fear test. 
Subjects who showed this extinction impairment also exhibited behavioural 
sensitisation to a subsequent systemic injection of amphetamine. The 
behavioural sensitisation seen in these subjects provides a possible candidate 
for the underlying neural change involved in the extinction impairment. This is 
consistent with the fact that drugs which facilitate the action of dopamine, like 
amphetamine, are able to induce the positive psychotic symptoms of 
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schizophrenia(Angrist, Sathananthan, Wilk & Gershon, 1974). Among the 
positive symptoms of schizophrenia are delusional thoughts, phobias and 
paranoid ideations. Neurochemical sensitisation of the mesolimbic 
dopaminergic system has been implicated as a contributing factor in the 
development of schizophrenia (Glenthoj & Hemmingsen, 1997, Lieberman, 
Sheitman & Kinon, 1997, Laurelle, 2000). The persistent fear seen in our 
subjects following the application of a dopaminergic agonist, amphetamine, 
could potentially be the result of a sensitised mesolimbic projection in these 
subjects. 
 
The extinction impairment following the application of amphetamine prior to 
extinction sessions, was not due to an increase in the expression of conditioned 
fear in subjects. This allows the possibility that the extinction impairment seen in 
this study was due to an effect of amphetamine on either extinction learning or 
the consolidation of extinction memory. As previously outlined amphetamine 
administration to the dopaminergic neurons of the VTA, has been shown to 
precipitate synaptic changes both inducing LTP (Saal et al., 2003) and blocking 
the induction of LTD (Jones et al., 2000). A pertinent question about synaptic 
alterations arises in relation to amphetamine, does the block of LTD by 
dopamine releasing drugs does in fact promote LTP? (Kauer, 2004) If so, what 
effect might this be having on the subjects ability to lose responsiveness to a 
previously relevant stimuli? To further clarify the extinction impairment found in 
our study an investigation into the synaptic changes occurring in vitro, following 
the repeated application of amphetamine, would nicely complement the findings 
of this study.   
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Additionally, the disparity in findings between the BLA and the VTA will need to 
be investigated more thoroughly to firmly establish whether this extinction 
impairment is truly a regionally specific one. This could have important 
ramifications for our understanding of the neural regions critical for extinction 
learning. One way to achieve this would be to manipulate other terminal regions 
of the meso-cortico-limbic pathway to more precisely establish the bounds of 
regional involvement. In addition, it would be interesting to replicate this study 
with a variety of other dopaminergic agents to more precisely establish the role 
of DA neurons in this extinction impairment. These possibilities alone or in 
conjunction provide a large variety of potential avenues to explore to better 
understand the extinction deficit found following the administration of 
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